# Bacterial EV & Enzyme Replacement Therapy

## REGULATORY GUIDE

A Detailed Overview of Regulatory Pathways for bEV & ERT Research and Therapeutic Applications

**AS OF:** October 2025

**PREPARED BY:**
NYU Abu Dhabi iGEM Team 2025

This guide provides future iGEM teams and researchers with comprehensive regulatory frameworks for developing enzyme replacement therapies (ERTs) and bacterial extracellular vesicle (EV) therapeutics in the United States and United Arab Emirates. The document covers research practices, clinical trial requirements, approval pathways, and specific considerations including halal certification requirements.

**Disclaimer:** This document provides general regulatory information and does not constitute legal or regulatory advice. Consult qualified regulatory professionals and legal counsel for specific project guidance.

# Part I: United States Regulatory Framework

## A. Enzyme Replacement Therapies (ERTs)

### 1. Governing Bodies and Framework

**Primary Regulatory Authority:** Food and Drug Administration (FDA) - The federal agency responsible for protecting public health by regulating and supervising the safety of drugs, biological products, and medical devices.

- **Center for Drug Evaluation and Research (CDER):** Reviews and approves new drugs and ensures marketed drugs remain safe and effective throughout their lifecycle.
- **Center for Biologics Evaluation and Research (CBER):** Regulates biological products including vaccines, blood products, and cellular therapies that are typically derived from living sources.

**Regulatory Classification:** ERTs are typically classified as biological products under 21 CFR Part 600, requiring Biologics License Applications (BLA) rather than New Drug Applications due to their complex protein structure and biological manufacturing processes.

### 2. Development Pathway

#### 2.1 Non-Clinical Studies

Non-clinical studies must demonstrate both pharmacological activity and safety before human testing can begin, following FDA guidance "Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment" (2019).

**Objectives:**

- **Pharmacodynamic characterization:** Proof-of-concept studies demonstrating successful enzyme replacement and establishing biologically active dosing ranges in relevant animal models.
- **Safety assessment:** Comprehensive toxicology studies evaluating potential adverse effects from the enzyme protein, modifications, or delivery mechanisms.

**Key Considerations for Study Design:**

- **Target clinical population:** Pediatric populations require additional safety considerations due to organ immaturity and developmental changes affecting drug distribution and metabolism.
- **Disease progression rates:** Rapidly progressive diseases may justify accelerated development timelines and acceptance of limited safety databases for first-in-human studies.
- **Animal model availability:** Both normal animals and disease-specific models (enzyme-deficient) should be used to assess biological activity and safety profiles.
- **Delivery device safety:** Novel delivery methods (intrathecal, intraventricular) require separate safety evaluation if not previously established.

**Required Studies per ICH M3(R2) Guidelines:**

- **Toxicology studies:** Single and repeat-dose studies in relevant species, typically rodent and non-rodent, with duration based on planned clinical trial length.
- **Immunogenicity assessment:** Evaluation of antibody formation potential and its impact on safety and efficacy, particularly important for recombinant human enzymes.
- **Genotoxicity evaluation:** Required for chemically modified ERTs (e.g., PEGylated enzymes) but typically not needed for unmodified recombinant human enzymes.

### 2.2 Clinical Development

**Investigational New Drug (IND) Application:** Required per 21 CFR Part 312 before any human studies, containing manufacturing information, animal study data, and clinical protocols.

**Phase I Trials:** First-in-human safety studies typically conducted in 20-100 patients, establishing maximum tolerated dose and preliminary pharmacokinetic profiles.

**Phase II Trials:** Efficacy demonstration in 100-300 patients with target disease, establishing optimal dosing regimens and continued safety monitoring with focus on immunogenicity.

**Phase III Trials:** Large-scale studies (300+ patients) confirming efficacy and safety for BLA submission, often compared to standard of care or placebo in rare diseases.

### 2.3 Pediatric Considerations

The Pediatric Research Equity Act (PREA) requires pediatric studies for new drugs likely to be used in children, with specific considerations for ERTs given that most inborn errors manifest in childhood.

- **Juvenile animal studies:** May be required per ICH S11 guidelines when adult animal data is insufficient to assess pediatric safety, particularly for developing organ systems.
- **Pediatric Investigation Plans:** Must be submitted to FDA outlining pediatric development strategy, including age-appropriate formulations and dosing.
- **Safety considerations:** Enhanced monitoring for growth, development, and organ-specific toxicities in immature systems.

## 3. Currently Approved ERTs in the USA

**Gaucher Disease (Glucocerebrosidase Deficiency):**

- **Cerezyme (Imiglucerase):** First approved ERT (1994), CHO cell-derived recombinant enzyme providing over 25 years of clinical experience with established long-term safety profile.
- **VPRIV (Velaglucerase alfa):** Human fibroblast-derived alternative (2010) offering similar efficacy with potentially different immunogenicity profile.
- **Elelyso (Taliglucerase alfa):** Plant cell-derived enzyme (2012) providing manufacturing diversity and reduced risk of human pathogen contamination.

**Fabry Disease (Alpha-galactosidase A Deficiency):**

- **Fabrazyme (Agalsidase beta):** CHO cell-derived enzyme (2003) administered every two weeks, demonstrated to reduce GL-3 accumulation and slow nephropathy progression.
- **Galafold (Migalastat):** Oral pharmacological chaperone (2018) that stabilizes specific mutant enzymes, representing an alternative approach to traditional ERT.

**Pompe Disease (Acid Alpha-glucosidase Deficiency):**

- **Myozyme/Lumizyme (Alglucosidase alfa):** CHO cell-derived enzyme (2006) improving survival in infantile-onset disease and motor function in late-onset disease.
- **Nexviazyme (Avalglucosidase alfa):** Next-generation ERT (2021) with enhanced mannose-6-phosphate targeting for improved muscle uptake and superior efficacy.

**Mucopolysaccharidoses (Various Enzyme Deficiencies):**

- **Aldurazyme (Laronidase):** MPS I treatment (2003) reducing GAG accumulation and improving respiratory function and joint mobility.
- **Elaprase (Idursulfase):** MPS II treatment (2006) demonstrating improvements in walking capacity and liver/spleen size reduction.

## B. Bacterial Extracellular Vesicle (EV) Therapeutics

### 1. Governing Framework

**Primary Authority:** FDA Center for Biologics Evaluation and Research (CBER), specifically the Office of Tissues and Advanced Therapies (OTAT) which regulates cellular and gene therapy products under 21 CFR Part 1271.

Bacterial EVs fall into a regulatory gray area, assessed case-by-case based on intended use, source organism, and mechanism of action.

### 2. Regulatory Classification

**As vaccines:** Follow precedent of bacterial OMV vaccines like Bexsero (Neisseria meningitidis), requiring demonstration of immunogenicity and safety through traditional vaccine development pathways.

**As drug delivery vehicles:** Regulated as biological products requiring IND submission with comprehensive CMC (Chemistry, Manufacturing, and Controls) data addressing EV characterization, purification, and batch consistency.

### 3. Key Requirements

**Manufacturing Standards per 21 CFR Part 600:**

- **GMP compliance:** Closed system manufacturing required to prevent contamination, with validated cleaning and sterilization procedures.
- **Characterization requirements:** Particle size distribution, protein content, endotoxin levels, and sterility testing must meet established specifications.
- **Potency assays:** Must demonstrate biological activity relevant to intended therapeutic effect, challenging given EV complexity and heterogeneity.

**Safety Considerations:**

- **Endotoxin removal:** Bacterial EVs require validated purification to remove lipopolysaccharide contamination below acceptable levels (<5 EU/kg).
- **Pathogenic component elimination:** Comprehensive screening for toxic proteins, nucleic acids, or other harmful bacterial components.
- **Immunogenicity assessment:** Evaluation of both beneficial immune activation and potential adverse hypersensitivity reactions.

### 4. Current Challenges

- **Classification ambiguity:** No established regulatory pathway specifically for bacterial EVs, leading to case-by-case assessments and potential delays.
- **Analytical limitations:** Current characterization methods cannot fully discriminate EV subtypes or predict biological activity, complicating potency assay development.

- **Manufacturing reproducibility:** EV heterogeneity makes batch-to-batch consistency challenging, requiring novel quality control approaches.

### 5. Precedent Cases

- **Bexsero vaccine:** FDA-approved (2015) Neisseria meningitidis OMV vaccine demonstrates regulatory acceptability of bacterial vesicle-based products for immunization.
- **Dendritic cell exosomes:** Phase I/II trials in melanoma demonstrate feasibility of EV-based therapeutics, though primarily using mammalian rather than bacterial sources.

# Part II: United Arab Emirates Regulatory Framework

## A. Enzyme Replacement Therapies (ERTs)

### 1. Governing Bodies

**Ministry of Health and Prevention (MOHAP):** Federal authority responsible for national drug registration, clinical trial oversight, and pharmaceutical manufacturing licensing throughout the UAE.

**Emirates Drug Establishment (EDE):** Established September 2023 as specialized federal authority assuming drug regulation responsibilities from MOHAP, implementing enhanced international alignment and innovation support.

**Department of Health Abu Dhabi (DoH):** Regional authority managing healthcare services and clinical trial approvals specifically within Abu Dhabi Emirate.

**Dubai Health Authority (DHA):** Regional authority overseeing healthcare regulation and clinical research activities within Dubai Emirate.

### 2. Research Practices Framework

#### 2.1 Good Clinical Practice (GCP) Compliance

All clinical trials must adhere to ICH E6(R2) guidelines, which provide unified standards for designing, conducting, recording, and reporting clinical trials involving human subjects.

**Core Requirements:**

- **Personnel certification:** All research staff must complete GCP training from approved organizations within three years, achieving minimum 80% examination scores to ensure competency.
- **Helsinki Declaration compliance:** Research must respect human dignity, autonomy, and welfare as outlined in the World Medical Association's ethical principles.
- **ISO 14155 compliance:** Medical device investigations must follow international standards for clinical investigation design and conduct.

**Quality Management Integration:**

- **Good Laboratory Practice (GLP):** Non-clinical studies must follow OECD principles ensuring data reliability and study integrity.
- **Good Manufacturing Practice (GMP):** Product manufacturing must meet WHO guidelines and local UAE Cabinet Resolution No. 20 of 2014 requirements.

### 2.2 Institutional Requirements

Research facilities must demonstrate adequate infrastructure, qualified personnel, and appropriate equipment for proposed studies. Contract Research Organizations (CROs) must obtain valid UAE business licenses and demonstrate compliance with international quality standards.

### 2.3 Investigator Qualifications

Principal investigators must hold valid UAE medical licenses from MOHAP, DHA, or DoH, demonstrating recognized specialization in the relevant therapeutic area. Investigators must allocate sufficient time and maintain adequate staffing to ensure proper trial conduct and patient safety monitoring.

## 3. Clinical Trial Requirements

### 3.1 Authorization Process

The multi-step approval process ensures both scientific merit and ethical acceptability before trial initiation.

1. **Ethics Committee opinion:** Independent review of trial design, risk-benefit assessment, and informed consent procedures.
2. **RCMOHP approval:** Regulatory Committee at MOHAP provides written authorization based on scientific and regulatory compliance review.
3. **Import/export licenses:** Drug Control Department issues permits for investigational products and biological sample transfers.

### 3.2 Ethics Committee Structure

**Higher Committee of Ethics (HCE):** Provides oversight and accreditation of ethics committees, conducting audits to ensure consistent ethical standards across the UAE.

**Regulatory Committee at MOHAP (RCMOHP):** Issues trial permissions and maintains regulatory oversight through mandatory progress reporting and inspection authority.

**Central/Local Ethics Committees:** Provide independent ethical review with mandated composition including medical professionals, legal experts, and lay representatives.

## 4. UAE-Specific Requirements

### 4.1 Halal Certification Framework

**Emirates Authority for Standardization and Metrology (ESMA):** Primary certification body implementing UAE.S 2055 series standards for halal pharmaceutical products.

**Dubai Municipality Food Safety Department:** Secondary certification authority providing halal compliance verification and market surveillance.

**Certification Process:**

1. **Application submission:** Complete product specifications, ingredient sourcing documentation, and manufacturing process descriptions.
2. **Documentation review:** Verification of halal compliance throughout the supply chain, including raw material certificates and processing aids.
3. **Factory inspection:** On-site audit of manufacturing facilities, equipment cleaning procedures, and contamination prevention measures.
4. **Laboratory testing:** Chemical analysis to confirm absence of prohibited substances including alcohol, pork derivatives, and other non-halal contaminants.
5. **Certification issuance:** UAE National Halal Mark authorization valid for 1-3 years, requiring renewal with updated compliance documentation.

**ERT-Specific Requirements:** All ingredients, excipients, and processing aids must meet halal criteria as defined in UAE.S 2055-4 standard. Manufacturing equipment

must be dedicated or undergo validated cleaning between halal and non-halal products to prevent cross-contamination.

### 4.2 Orphan Drug Designation

**Fast-Track Registration:** Implemented January 2018 to accelerate access to treatments for rare diseases affecting fewer than 1 in 2,000 individuals in the UAE population.

**Qualification Criteria:**

- **Rare disease treatment:** Products addressing conditions with limited therapeutic options and significant unmet medical need.
- **Innovation requirement:** New active ingredients with patent protection, ensuring genuine therapeutic advancement.
- **International precedent:** Positive regulatory opinion from FDA, EMA, or other recognized authorities demonstrating established safety and efficacy.

**Evaluation Timeline:**

- **Technical review:** Drug Registration Committee completes comprehensive assessment within 15 working days of complete submission.
- **Decision notification:** Final approval or rejection communicated within 10 working days following technical evaluation completion.

**Multi-Criteria Decision Analysis (MCDA) Tool:** Quantitative framework weighing ten factors to optimize resource allocation for rare disease treatments:

- **Cost-effectiveness (25.1%):** Economic value considering treatment costs versus health benefits achieved.
- **Health gain magnitude (20.1%):** Clinical benefit size measured through validated outcome measures and quality-adjusted life years.
- **Therapeutic alternatives (14.3%):** Availability and effectiveness of existing treatment options for the target condition.

## 5. Currently Approved ERTs in UAE

**5.1 Market Overview** The UAE ERT market generated $52.4 million in 2024, with projected growth to $90.5 million by 2030 representing 9.7% compound annual growth rate driven by increased diagnosis and treatment access.

**5.2 Disease Prevalence Patterns** UAE population shows unique lysosomal storage disorder prevalence due to consanguineous marriages and founder effects:

- **Overall LSD prevalence:** 26.9 per 100,000 live births among Emirati citizens, significantly higher than global averages.
- **GM1-gangliosidosis:** 4.7 per 100,000 representing highest individual disease prevalence requiring specialized treatment protocols.
- **Pompe disease:** 2.7 per 100,000 similar to European populations, indicating genetic diversity in disease susceptibility.

**5.3 Approved Products by Therapeutic Area**

**Gaucher Disease:**

- **Cerezyme (Imiglucerase):** Largest revenue generator in UAE ERT market, providing established treatment for Type 1 disease with demonstrated long-term safety.
- **VPRIV (Velaglucerase alfa):** Alternative option offering similar efficacy with potential for reduced immunogenicity in treatment-naive patients.

**Fabry Disease:**

- **Fabrazyme (Agalsidase beta):** Primary ERT approved for patients 2 years and older, requiring specialized infusion facilities and regular monitoring for infusion reactions.

**Pompe Disease:**

- **Myozyme (Alglucosidase alfa):** Standard treatment demonstrating improved respiratory function and motor development in both infantile and late-onset forms.

- **Nexviadyme (Avalglucosidase alfa):** Next-generation ERT with enhanced muscle targeting approved based on superior efficacy compared to standard treatment.

## B. Bacterial Extracellular Vesicle (EV) Therapeutics

### 1. Governing Bodies

**MOHAP Drug Department:** Responsible for novel therapeutic product registration and manufacturing oversight, applying existing biological product frameworks to EV therapeutics.

**Department of Health Abu Dhabi (DoH):** Manages regional clinical trial approvals and has supported EV-related research through the Abu Dhabi Stem Cell Center.

**Dubai Health Authority (DHA):** Oversees Dubai-based research activities and has supported EV diagnostic development through Dubai Future Accelerators program.

### 2. Regulatory Framework

**Current Classification:** EVs assessed under "biological products" or "advanced therapy medicinal products" categories, depending on source, modification, and intended therapeutic application.

**Federal Law No. (4) of 1983:** Governs pharmaceutical products and pharmacy profession, establishing basic requirements for drug registration, manufacturing, and distribution that apply to novel EV therapeutics.

**As Vaccines:** Bacterial EV vaccines would follow established immunization product pathways, requiring demonstration of immunogenicity, safety, and appropriate manufacturing controls.

**As Therapeutics:** Require comprehensive technical dossiers including safety data, efficacy evidence, manufacturing information, and quality control procedures similar to other biological products.

### 3. Key Framework Elements

**Manufacturing Requirements:**

- **GMP certification:** UAE Cabinet Resolution No. 20 of 2014 mandates Good Manufacturing Practice compliance for all pharmaceutical manufacturing facilities.
- **Site licensing:** Manufacturing facilities must obtain approval from MOHAP or relevant local health authorities before production initiation.
- **Batch documentation:** Complete records of production, testing, and release must be maintained according to ICH Q-series guidelines.

**Quality Standards:**

- **ICH Q-series alignment:** Manufacturing quality standards must follow international guidelines for analytical procedures, validation, and quality risk management.
- **Post-market surveillance:** MOHAP Pharmacovigilance Center requires adverse event reporting and periodic safety updates for all approved products.

### 4. Current Regulatory Environment

**Policy Development:** UAE applies WHO and EMA biological product guidelines to novel therapies while developing local expertise in advanced therapeutic assessment.

**Innovation Support:** National agenda biotechnology incentives provide a framework for accelerated assessment of innovative products including cell and gene therapies adjacent to EV technologies.

**Infrastructure Development:** Academic institutions including Khalifa University and UAE University conduct EV research, building local regulatory familiarity with the technology.

### 5. Regulatory Challenges

**Classification uncertainty:** Absence of specific EV guidance requires case-by-case assessment, potentially creating inconsistent regulatory approaches and development timelines.

**Technical infrastructure:** Limited availability of specialized analytical laboratories and clinical trial sites capable of supporting EV therapeutic development and assessment.

**Regulatory expertise:** Growing biotech sector requires continued development of reviewer expertise in novel therapeutic platforms including bacterial EV technologies.

# Part III: Comparative Analysis and Strategic Recommendations

## Regulatory Pathway Comparison

| Aspect | United States | United Arab Emirates |
|---|---|---|
| **Primary Authority** | FDA (CDER/CBER) | MOHAP/EDE, DoH, DHA |
| **ERT Pathway** | BLA under 21 CFR Part 600 | Technical dossier under Federal Law No. 4/1983 |
| **EV Classification** | Case-by-case under CBER | Biological products framework |
| **Orphan Designation** | Orphan Drug Act (7-year exclusivity) | Fast-track registration (15-day review) |
| **Cultural Requirements** | None | Halal certification mandatory (UAE.S 2055-4) |
| **Pediatric Requirements** | PREA mandatory assessments | ICH guidelines with local adaptation |

## Strategic Recommendations for iGEM Teams

### 1. Early Regulatory Engagement

Initiate discussions with regulatory authorities during preclinical development to clarify classification and pathway requirements. For UAE development, engage ESMA early for halal certification planning to avoid manufacturing delays.

### 2. Manufacturing Strategy

Design GMP-compliant processes from development initiation, considering both US 21 CFR Part 600 and UAE Cabinet Resolution No. 20 requirements. For Muslim-majority markets, implement halal-compliant supply chains including dedicated equipment or validated cleaning procedures.

### 3. Clinical Development Planning

Leverage orphan drug pathways where applicable, noting UAE's faster 15-day review versus US 7-year exclusivity benefits. Consider regional disease prevalence patterns when designing trials, particularly for lysosomal storage disorders with higher UAE prevalence.

## Part IV: Future Regulatory Developments

### United States

FDA continues developing EV-specific guidance documents addressing manufacturing standardization, characterization requirements, and clinical development pathways. Enhanced focus on manufacturing quality standards and analytical method validation for complex biological products.

### United Arab Emirates

Emirates Drug Establishment (EDE) modernization includes streamlined authorization processes, enhanced intellectual property protection, and strengthened pharmacovigilance systems. Digital health integration initiatives include electronic submission systems and AI-assisted regulatory review processes.

## Key References

- 21 CFR Part 312 - Investigational New Drug Application
- 21 CFR Part 600 - Biological Products: General
- ICH E6(R2) - Good Clinical Practice Guidelines
- ICH M3(R2) - Nonclinical Safety Studies Guidelines
- ICH S11 - Nonclinical Safety Testing for Pediatric Pharmaceuticals
- UAE.S 2055-4 - Halal Certification for Pharmaceutical Products
- UAE Cabinet Resolution No. 20 of 2014 - Pharmaceutical Manufacturing Regulations
- Federal Law No. (4) of 1983 - UAE Pharmaceutical and Pharmacy Profession Law
- ISO 14155 - Clinical Investigation of Medical Devices for Human Subjects